Nitric Oxide Increases Glucose Uptake Through a Mechanism That Is Distinct From the Insulin and Contraction Pathways in Rat Skeletal Muscle
- From the Research Division, Joslin Diabetes Center; Department of Medicine, Brigham and Women's Hospital; and Harvard Medical School, Boston, Massachusetts.
- Address correspondence and reprint requests to Laurie J. Goodyear, PhD, Research Division, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215. E-mail: laurie.goodyear{at}joslin.harvard.edu .
Abstract
Insulin, contraction, and the nitric oxide (NO) donor, sodium nitroprusside (SNP), all increase glucose transport in skeletal muscle. Some reports suggest that NO is a critical mediator of insulin- and/or contraction-stimulated transport. To determine if the mechanism leading to NO-stimulated glucose uptake is similar to the insulin- or contraction-dependent signaling pathways, isolated soleus and extensor digitorum longus (EDL) muscles from rats were treated with various combinations of SNP (maximum 10 mmol/l), insulin (maximum 50 mU/ml), electrical stimulation to produce contractions (maximum 10 min), wortmannin (100 nmol/l), and/or the NO synthase (NOS) inhibitor NG-monomethyl-L-arginine (L-NMMA) (0.1 mmol/l). The combinations of SNP plus insulin and SNP plus contraction both had fully additive effects on 2-deoxyglucose uptake. Wortmannin completely inhibited insulinstimulated glucose transport and only slightly inhibited SNP-stimulated 2-deoxyglucose uptake, whereas L-NMMA did not inhibit contraction-stimulated 2-deoxyglucose uptake. SNP significantly increased the activity of the α1 catalytic subunit of 5′ AMP-activated protein kinase (AMPK), a signaling molecule that has been implicated in mediating glucose transport in fuel-depleted cells. Addition of the NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) (1 mg/ml) to the drinking water of rats for 2 days failed to affect the increase in muscle 2-deoxyglucose uptake in response to treadmill exercise. These data suggest that NO stimulates glucose uptake through a mechanism that is distinct from both the insulin and contraction signaling pathways.
Footnotes
-
AMPK, AMP-activated protein kinase; EDL, extensor digitorum longus; eNOS, endothelial nitric oxide synthase; KRBB, Krebs-Ringer bicarbonate buffer; L-NAME, NG-nitro-L-arginine methyl ester; L-NMMA, NG-monomethyl-L-arginine; NO, nitric oxide; NOS, NO synthase; nNOS, neuronal NOS; P13K, phosphatidylinositol 3-kinase; SNP, sodium nitroprusside.
-
- Accepted October 24, 2000.
- Received February 4, 2000.
- by the American Diabetes Association, Inc.











